Stereotaxis Earns FDA Clearance, Launches System

Stereotaxis has received FDA clearance for its Synchrony system, marking a significant milestone for the company. This clearance allows for the launch of the new platform, which is expected to enhance robotic cardiology procedures. The Synchrony system aims to provide physicians with improved control and precision during minimally invasive treatments. This regulatory approval and subsequent launch position Stereotaxis to advance its offerings in the medical technology market, potentially improving patient outcomes and expanding its market presence.